Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global ...

More than 30 years ago, when Jean-Pascal Tricoire first came to China, his friends gave him the Chinese ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...

The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6 ...

PEPFAR, the campaign to end H.I.V. globally, would morph into an effort to detect disease outbreaks and sell American products, according to documents obtained by The Times.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

The Global Cardiovascular Disease Market, valued at approximately USD 171.55 million in 2023, is projected to expand at a steady compound annual growth rate (CAGR) of 5% during the forecast period ...